73
Participants
Start Date
April 28, 2015
Primary Completion Date
January 29, 2020
Study Completion Date
March 7, 2022
PF-04449913 (Glasdegib)
Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
Azacitidine
75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
Ziekenhuis Netwerk Antwerpen - Campus Stuivenberg, Antwerp
UZ Leuven, Leuven
Montefiore Einstein Center for Cancer, The Bronx
Montefiore Medical Center, The Bronx
Stony Brook University Hospital Cancer Center, Stony Brook
Stony Brook University, Stony Brook
Roswell Park Cancer Institute, Buffalo
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Duke University Health System: Adult Bone Marrow Transplant Clinic, Durham
Duke University Health System, Duke University Hospital, Durham
Duke University Health System, Durham
Investigational Chemotherapy Service, Durham
University of Alabama at Birmingham the Kirklin Clinic, Birmingham
University of Alabama at Birmingham, Birmingham
CHU de Tours-Hopital Bretonneau-Centre Regional de cancerologie Henry Kaplan, Tours
Henry-Joyce Cancer Center, Nashville
Vanderbilt - Ingram Cancer Center, Nashville
Staedtisches Klinikum Braunschweig gGmbH, Braunschweig
Cleveland Clinic Taussig Cancer Center, Cleveland
Hospices Civils de Lyon - Hopital Lyon Sud- Hematologie, Pierre-Bénite
Hopital Saint-Louis (AP-HP) - Service Hematologie Senior, Paris
CHU d'Amiens-Picardie - Hopital SUD, Amiens
Huntsman Cancer Hospital, Salt Lake City
Huntsman Cancer Institute, Salt Lake City
UC San Diego Moores Cancer Center, La Jolla
Seattle Cancer Care Alliance (SCCA), Seattle
University of Washington Medical Center (UWMC), Seattle
University Of Alberta Hospital, Edmonton
Smilow Cancer Center at Yale New Haven Hospital, New Haven
Tom Baker Cancer Center, Calgary
King's College Hospital, London
The Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne
Oxford University Hospitals NHS Foundation Trust, Oxford
Lead Sponsor
Pfizer
INDUSTRY